Bring the full picture
Gather prior results, imaging, pathology and your current medicine and supplement list.
Organize my records →MODERN BIO / TESTING LAB / PRECISION ONCOLOGY
Emerging + use-dependentAdvanced
cancer testing.
Start with the clinical question—not the most comprehensive panel.RGCC International offers liquid-biopsy and molecular tests that examine circulating tumor cells and related cancer signals. Some are positioned for early detection; others for monitoring known cancer or exploring treatment sensitivity. Those are different decisions with different evidence, risks and follow-up needs.
01 / START HERE
What brings you here?
Choose a situation to focus the guide. This organizes the information; your clinician determines whether a test is appropriate.Not sure which situation fits?
You can browse all six tests below or use the questions to prepare for a clinician conversation.
Help me prepare →Keep standard care in place.
These tests do not replace mammography, colonoscopy or FIT, cervical screening, low-dose CT, pathology or imaging. A detected signal needs conventional clinical evaluation and confirmation. No therapy, supplement or oncology plan should change from this report alone.
02 / UNDERSTAND THE OPTIONS
What does each test look for?
Open a test for its purpose and limits. These are RGCC’s reported uses, not a recommendation to order. Confirm current panels, specimens, methods and availability with RGCC and your ordering clinician.Screening signalOnco-D-Clare+
What RGCC reports
Designed by RGCC for early-detection risk signals before symptoms.
What to keep in view
Does not diagnose cancer, cover every cancer or replace organ-specific screening.
Baseline + broad monitoringOncotrace+
What RGCC reports
Evaluates circulating tumor cell count, phenotype and stemness markers.
What to keep in view
Interpret changes with tumor type, stage, treatment, imaging and the same laboratory method.
Treatment-response monitoringOncocount+
What RGCC reports
Measures the presence and concentration of circulating tumor cells.
What to keep in view
A count alone does not establish treatment success, recurrence or progression.
Cancer-specific monitoringOncotrail RGCC+
What RGCC reports
Tracks markers associated with selected cancers, including breast, colon, GI, lung, melanoma, prostate and sarcoma.
What to keep in view
Availability and clinical fit depend on the confirmed cancer type and the treating clinician's plan.
Conventional therapy profilingOnconomics+
What RGCC reports
RGCC reports cellular and molecular sensitivity to selected chemotherapy and targeted agents.
What to keep in view
An ex-vivo result is one input; it is not a prescription or proof of patient benefit.
Expanded therapy profilingOnconomics Plus+
What RGCC reports
Adds RGCC-reported sensitivity to selected natural substances and other modalities.
What to keep in view
Natural does not mean safe or compatible. Oncology and pharmacy review are essential.
03 / PREPARE YOUR NEXT STEP
Start with a conversation.
A qualified clinician decides whether to order, how to interpret and what happens next. Modern Bio can help you organize records; coordinated oncology testing is not an available ordering service here.Name the decision
Ask what the result would change, what evidence supports it and what the complete cost would be.
Open the question checklist →Agree on follow-up
Know who will interpret the report, confirm a finding and explain the next step.
Understand possible results →See the complete seven-step testing workflow
Future coordination should organize the record and route requests. Clinical decisions remain with the qualified oncology team.
- 01Clarify the situation
Symptoms, no known cancer, confirmed diagnosis, active treatment or post-treatment surveillance.
- 02Assemble the source record
Pathology, stage, imaging, prior biomarkers, inherited risk, treatments, medicines and supplements.
- 03Practitioner eligibility review
Confirm that the test can answer a defined question and that the correct oncology team is involved.
- 04Test-specific consent
Review evidence, limits, privacy, full cost, possible results and downstream diagnostic burden.
- 05Qualified collection + laboratory processing
Use the exact specimen, handling and shipping requirements for the selected assay.
- 06Reconcile the report
Compare it with pathology, imaging, authorized biomarkers, symptoms and clinical guidelines.
- 07Document the next decision
Confirm, monitor, repeat, refer or take no action—with an owner and timeline for follow-up.
READING A REPORT
What could the result mean?
A report needs context and a clinician-owned next step.Explore detected, negative and sensitivity results
Confirm—do not label.
A screening signal is not proof of cancer. It should trigger a coordinated diagnostic pathway, which may include imaging, endoscopy or tissue biopsy depending on the predicted site and clinical context.
Continue standard care.
A negative blood result does not exclude cancer, clear concerning symptoms or cancel recommended screening. Early cancers may release too little circulating material for detection.
Reconcile—do not prescribe.
Laboratory response categories must be weighed against the cancer type, stage, patient health, drug approval, dosing evidence, interactions and the treating oncologist's plan.
04 / TAKE THIS TO YOUR CLINICIAN
Make the conversation count.
Use this checklist before payment or sample collection. A credible testing pathway welcomes specific questions about evidence, cost and follow-up.Open the 10-question appointment checklist
- 01
What exact decision will this result change?
- 02
Is this intended for screening, monitoring, recurrence surveillance or treatment selection?
- 03
What evidence supports this exact test in my cancer type and stage?
- 04
What is the test's regulatory and laboratory status where I live?
- 05
What are its sensitivity, specificity and false-positive or false-negative risks?
- 06
How will a result be confirmed with pathology, imaging or an authorized diagnostic?
- 07
Who will interpret the report and own follow-up?
- 08
Will my oncologist review it before any treatment or supplement changes?
- 09
What is the complete cost, including repeat testing and downstream workup?
- 10
How are my sample, genetic data and results stored, shared and deleted?
START WITH WHAT IS ALREADY PROVEN
Build the complete cancer-prevention record first.
Keep standard screening current, capture family history and prior results, then decide whether an advanced test adds information that could genuinely change care.CHECK THE EVIDENCE
Sources behind the guide.
RGCC pages explain what the company says each assay is designed to do. NCI and FDA sources provide the broader evidence and regulatory context needed to interpret those claims responsibly.View all seven primary and official sources
RGCC INTERNATIONALCancer test portfolio↗RGCC INTERNATIONALOncotrace test information↗RGCC INTERNATIONALOncocount test information↗RGCC INTERNATIONALOnconomics test information↗NATIONAL CANCER INSTITUTEQuestions and answers about multi-cancer detection tests↗NATIONAL CANCER INSTITUTEHow authorized liquid biopsies guide treatment↗U.S. FOOD AND DRUG ADMINISTRATIONAuthorized oncology companion diagnostics↗